tiprankstipranks
Trending News
More News >
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) AI Stock Analysis

Compare
1,714 Followers

Top Page

CT

Citius Pharmaceuticals

(NASDAQ:CTXR)

Rating:38Underperform
Price Target:
Citius Pharmaceuticals' overall stock score reflects the challenging financial performance and bearish technical indicators. The company's ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock's downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
Positive Factors
Clinical Trials
Mino-Lok has demonstrated an improvement in treatment of CRBSI, achieving its primary endpoint in the Phase 3 study.
Commercialization
Citius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory Progress
The FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Negative Factors
Financial Constraints
Citius Pharma needs to secure additional capital prior to a launch of Lymphir.
Financial Performance
The company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.
Regulatory and Development Timelines
Completing the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)

Citius Pharmaceuticals Business Overview & Revenue Model

Company DescriptionCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
How the Company Makes MoneyCitius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary
Citius Pharmaceuticals faces significant challenges typical of early-stage biotech firms, with ongoing losses and reliance on external financing. The company's financial health is stable in terms of assets and equity, but cash burn and lack of revenue generation remain critical concerns. Future success hinges on achieving revenue growth and improving operational efficiency.
Income Statement
30
Negative
Citius Pharmaceuticals shows a challenging income statement with negative gross profit and net income, primarily due to high operating expenses. The company has not yet generated significant revenue, with the most recent TTM (Trailing-Twelve-Months) total revenue being minimal. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies. Revenue growth is difficult to assess due to negligible sales figures.
Balance Sheet
45
Neutral
The balance sheet reflects a moderate financial structure with a reasonable debt-to-equity ratio and positive equity. However, the company has been relying heavily on equity financing, as evidenced by frequent capital raises, which could dilute shareholder value. The equity ratio remains strong, indicating a solid foundation of assets relative to liabilities.
Cash Flow
35
Negative
Citius Pharmaceuticals has a negative free cash flow and operating cash flow, highlighting cash burn issues typical for biotechnology companies in development phases. The cash flow from financing activities indicates reliance on external funding. There is no positive free cash flow growth, and the operating cash flow to net income ratio suggests inefficiencies in converting income to cash.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue155.93K0.000.000.000.000.00
Gross Profit-104.92K0.00-194.32K-179.68K-164.87K-152.36K
EBITDA-42.53M-38.64M-31.77M-32.88M-22.88M-17.38M
Net Income-39.68M-39.43M-32.54M-33.64M-23.13M-17.67M
Balance Sheet
Total Assets120.70M116.65M103.61M114.00M142.43M43.77M
Cash, Cash Equivalents and Short-Term Investments1.10M3.25M26.48M41.71M70.07M13.86M
Total Debt204.57K262.87K481.25K678.23K855.47K1.35M
Total Liabilities51.78M42.55M12.18M10.57M9.65M10.10M
Stockholders Equity65.41M70.08M90.83M102.83M132.18M33.67M
Cash Flow
Free Cash Flow-26.79M-28.20M-29.06M-28.36M-64.26M-16.93M
Operating Cash Flow-26.79M-28.20M-29.06M-28.36M-24.25M-16.93M
Investing Cash Flow-5.00M-5.00M0.000.00-40.01M-1.83K
Financing Cash Flow12.55M9.97M13.83M0.00120.47M22.90M

Citius Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.21
Price Trends
50DMA
0.96
Positive
100DMA
1.26
Positive
200DMA
3.91
Negative
Market Momentum
MACD
0.28
Negative
RSI
79.64
Negative
STOCH
93.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Positive. The current price of 2.21 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 0.96, and below the 200-day MA of 3.91, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 79.64 is Negative, neither overbought nor oversold. The STOCH value of 93.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTXR.

Citius Pharmaceuticals Risk Analysis

Citius Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Citius Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
¥342.56B10.47-2.86%2.57%11.81%-7.17%
44
Neutral
$18.10M-97.30%-3.23%38.05%
42
Neutral
$15.98M-92.35%-85.48%45.13%
39
Underperform
$15.12M249.03%-14.43%16.04%
38
Underperform
$24.70M-60.06%8.99%
35
Underperform
$3.06M-135.33%-51.32%-1.76%
33
Underperform
$12.69M-339.64%-75.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTXR
Citius Pharmaceuticals
2.21
-12.84
-85.32%
PSTV
Plus Therapeutics
0.30
-1.20
-80.00%
MTVA
MetaVia
0.65
-3.96
-85.90%
MRKR
Marker Therapeutics
1.60
-3.05
-65.59%
SPRB
Spruce Biosciences
0.07
-0.50
-87.72%
SABS
SAB Biotherapeutics
1.72
-1.13
-39.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025